Armistice Capital Reports 5.94% Stake in Autolus Therapeutics plc

On May 15, 2026, Armistice Capital, LLC and Steven Boyd filed a Schedule 13G/A reporting a significant position in Autolus Therapeutics plc (AUTL). The reporting persons disclosed beneficial ownership of 15,800,000 American Depositary Shares, representing approximately 5.94% of the company's outstanding shares. This filing marks an increase from a previously reported zero position, crossing the 5% ownership threshold. The shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital, LLC serves as the investment manager. Steven Boyd, as the managing member of Armistice Capital, LLC, shares voting and dispositive power over these securities. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. The event triggering this specific filing occurred on March 31, 2026. Autolus Therapeutics is a biopharmaceutical company based in London, UK, specializing in T-cell therapies.